Efficacy and Tolerability of Tenofovir/Lamivudine/Dolutegravir among Antiretroviral Therapy Naive Human Immunodeficiency Virus Infected Patients of a Tertiary Care Center in Eastern India.

Journal: The Journal of the Association of Physicians of India
PMID: 38700305

Abstract

BACKGROUND: Although many drug regimens have been used in the treatment of human immunodeficiency virus (HIV) infection, the National AIDS Control Organization (NACO) of India recommends the use of a fixed-dose combination of tenofovir/lamivudine/dolutegravir (TLD) as a first-line regimen since 2020. In spite of much global data on the use of this combination, experience in the Indian population is still limited. We aim to find out the efficacy and tolerability of this novel regimen, in a tertiary care center of Eastern India.

Authors

  • Debroop Sengupta
    Associate Professor, Department of General Medicine, IPGMER & SSKMH, Kolkata, West Bengal, India.
  • Sandip Ghosh
    Junior Resident, Department of General Medicine, IPGMER & SSKMH, Kolkata, West Bengal, India, Corresponding Author.
  • Shantasil Pain
    Professor, Department of General Medicine, IPGMER & SSKMH, Kolkata, West Bengal, India.
  • Nandini Chatterjee
    Professor, Department of General Medicine, IPGMER & SSKMH, Kolkata, West Bengal, India.

Keywords

External Resources

Popular Topics
Recent Journals